A Phase 3 interventional study of Suraxavir marboxil and Oseltamivir Placebo in Influenza, sponsored by Capital Medical University. Recruiting at 2 sites in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by Capital Medical University · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing oseltamivir in Influenza, Human — 3 open to participants now, 5 under way, 3 of them phase 3. Oseltamivir · Influenza, Human.
Among the 59 studies testing oseltamivir in Influenza, Human, this one is the 15th largest by planned enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2025, is one of 10 in phase 3, and was the 58th registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →3 of the 59 studies testing oseltamivir in Influenza, Human are open now, in 5 countries. Recruiting first, the newest first:
University of Oxford · Sites in Brazil, Laos, Nepal and 1 more country
Ages 18–60
Capital Medical University · Sites in China
Ages 2+ · Healthy volunteers
By country, each count listing its studies:
Oseltamivir: first FDA approval 1999 (TAMIFLU), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 16 · Phase 3 11 · Phase 4 20
First in 2005; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 384 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 118 across the 58 interventional studies. Of the 44 that completed or were terminated, 20 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 59 have an industry lead sponsor. The 10 most frequent:
Capital Medical University is the lead sponsor of 296 studies on the registry; 90 are open to participants now.
12 studies in Influenza, Human by Capital Medical University: 7 open now, 7 under way, 3 of them phase 3. Of 4 finished, 0 (0%) have results posted.
Among the 12 studies in Influenza, Human by Capital Medical University, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 3, and was the 9th registered.
Capital Medical University’s Influenza, Human studies by the year they started, since 2009.
2 of the studies testing oseltamivir in Influenza, Human that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07236814Phase 3Capital Medical UniversitySuraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting | 2027-03-01 |
| NCT05648448University of OxfordA Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 59 studies testing oseltamivir in Influenza, Human, from their registry updates:
Among Capital Medical University’s 12 in Influenza, Human:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the efficacy of antiviral prophylaxis in preventing in-hospital influenza transmission. We will enroll hospitalized patients with confirmed influenza (index cases) and their uninfected roommates (room contacts). These room contacts will be randomized in a 1:1:1 ratio to one of three prophylactic groups: placebo, suraxavir marboxil, or oseltamivir. The primary outcome will be the rate of influenza infection among the room contacts, which will be monitored to determine the effectiveness of the interventions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(1)Inclusion Criteria for Index Cases:
① Patients hospitalized at a participating medical institution.
The subject and/or their legal guardian agrees to participate in this clinical study, has signed the form, and is able to comply with the protocol requirements for follow-up and complete all study procedures and assessments.
Age ≥ 2 years.
Positive for influenza virus as determined by a Rapid Antigen Test (RAT) or Nucleic Acid Amplification Test (NAAT) on a respiratory specimen (e.g., oropharyngeal swab, nasopharyngeal swab, sputum, or bronchoalveolar lavage fluid).
(2) Inclusion Criteria for Room Contacts:
① Patients hospitalized at a participating medical institution.
The subject and/or their legal guardian agrees to participate in this clinical study, has signed the informed consent form, and is able to comply with the protocol requirements for follow-up and complete all study procedures and assessments.
③ Age ≥ 12 years.
Expected to remain hospitalized for ≥ 72 hours.
Shares a room with at least one hospitalized index case who has been confirmed with influenza virus infection by RAT or NAAT on a respiratory specimen within the last 120 hours and developed influenza-related symptoms within the last 120 hours, and is expected to share the same room for ≥ 24 hours.
⑥ Negative for influenza virus as determined by a Nucleic Acid Amplification Test (NAAT) on a throat swab collected on Day 1.
3.Exclusion Criteria
(1) Index Cases There are no exclusion criteria for index cases. (2) Exclusion Criteria for Room Contacts:
Room contacts who have been diagnosed with or have had an influenza virus infection in the past 12 weeks.
Use of any anti-influenza antiviral drugs within 2 weeks prior to screening, including: neuraminidase inhibitors, polymerase inhibitors, hemagglutinin inhibitors, and M2 ion channel blockers (e.g., Oseltamivir, Zanamivir, Peramivir, Favipiravir, Arbidol, Baloxavir Marboxil, Amantadine, or Rimantadine, or other anti-influenza drugs approved by the NMPA).
Known to be pregnant or breastfeeding. (Subjects who suspect they may be pregnant must report this to the investigator, who will confirm with a pregnancy test).
History of fever (axillary temperature ≥ 37.3°C) within 72 hours prior to screening.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will be randomized to receive suraxavir marboxil placebo (40mg on the first day) and oseltamivir (75mg each day during the first five days).
Drug: Oseltamivir · Drug: Suraxavir marboxil placebo
All subjects will be randomized to receive oseltamivir placebo(75mg each day during the first five days) and suraxavir marboxil (40mg on the first day).
Drug: Suraxavir marboxil · Drug: Oseltamivir
All subjects will be randomized to receive oseltamivir placebo(75mg each day during the first five days) and suraxavir marboxil placebo (40mg on the first day).
Drug: Oseltamivir Placebo · Drug: Suraxavir marboxil placebo
Suraxavir marboxil (40mg on the first day)
Oseltamivir placebo(75mg each day during the first five days)
Oseltamivir (75mg each day during the first five days)
Suraxavir marboxil placebo (40mg on the first day).
The proportion of room contacts who develop clinical influenza within 5 days, with a virus subtype consistent with that of the index case.
The proportion of room contacts who develop clinical influenza\* within 5 days, with a virus subtype consistent with that of the index case. \*Clinical influenza is defined as a positive influenza virus detection by Rapid Antigen Test (RAT) or Nucleic Acid Amplification Test (NAAT), accompanied by at least one respiratory symptom (fever or chills, muscle or joint pain, headache, fatigue) and at least onesystemic symptom (cough, nasal congestion, sore throat).
Time frame: within 5 days
The proportion of room contacts who develop clinical influenza (as defined above) within 10 days
The proportion of room contacts who develop clinical influenza (as defined above) within 10 days, with a virus subtype consistent with that of the index case.
Time frame: within 10 days
The proportion of room contacts with laboratory-confirmed influenza within 5 days
The proportion of room contacts with laboratory-confirmed influenza (defined as a positive influenza virus RAT or NAAT result, regardless of symptoms) within 5 days, with a virus subtype consistent with that of the index case.
Time frame: Within 5 days
The incidence of post-treatment changes in the influenza virus sequence
Among room contacts who become infected with influenza virus within 10 days, the incidence of post-treatment changes in the influenza virus sequence (based on viral sequence analysis). This includes the incidence of events such as the I38T amino acid substitution, the H275Y amino acid substitution, and other emerging amino acid substitutions in the PA and NA sequences.
Time frame: Within 10 days
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Mar 2027, 15 months after the start.
Of 35 non-industry phase 3 interventional studies under Influenza, Human, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 41. This study's planned 15 months is close to that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oseltamivir